OR Royalties Inc. (NYSE:OR) Receives $35.75 Consensus PT from Analysts

OR Royalties Inc. (NYSE:OR) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $35.75.

OR has been the topic of a number of recent analyst reports. Raymond James Financial raised shares of OR Royalties from a “market perform” rating to an “outperform” rating and set a $41.00 target price on the stock in a research report on Thursday, November 6th. Canaccord Genuity Group raised shares of OR Royalties from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 22nd. Weiss Ratings restated a “buy (b)” rating on shares of OR Royalties in a report on Monday, December 29th. Wall Street Zen upgraded shares of OR Royalties from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 3rd. Finally, Zacks Research lowered OR Royalties from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th.

Institutional Trading of OR Royalties

A number of institutional investors and hedge funds have recently bought and sold shares of OR. Forge First Asset Management Inc. purchased a new position in OR Royalties in the second quarter worth approximately $2,385,000. CWA Asset Management Group LLC raised its holdings in shares of OR Royalties by 112.6% in the 3rd quarter. CWA Asset Management Group LLC now owns 381,747 shares of the basic materials company’s stock valued at $15,300,000 after purchasing an additional 202,173 shares in the last quarter. Synergy Asset Management LLC raised its holdings in shares of OR Royalties by 200.0% in the 3rd quarter. Synergy Asset Management LLC now owns 52,851 shares of the basic materials company’s stock valued at $2,118,000 after purchasing an additional 35,234 shares in the last quarter. Horizon Kinetics Asset Management LLC lifted its position in shares of OR Royalties by 6.7% during the 2nd quarter. Horizon Kinetics Asset Management LLC now owns 1,817,501 shares of the basic materials company’s stock worth $46,728,000 after purchasing an additional 114,464 shares during the last quarter. Finally, Trexquant Investment LP acquired a new position in shares of OR Royalties during the first quarter worth $248,000. 68.52% of the stock is currently owned by hedge funds and other institutional investors.

OR Royalties Stock Performance

Shares of OR Royalties stock opened at $38.57 on Wednesday. The stock has a 50 day moving average of $34.56 and a 200 day moving average of $33.01. The firm has a market capitalization of $7.22 billion, a price-to-earnings ratio of 48.83 and a beta of 0.78. OR Royalties has a fifty-two week low of $17.55 and a fifty-two week high of $42.25.

OR Royalties (NYSE:OR) last posted its earnings results on Wednesday, November 5th. The basic materials company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.03. The company had revenue of $71.63 million for the quarter, compared to the consensus estimate of $53.85 million. OR Royalties had a return on equity of 10.67% and a net margin of 60.72%. Analysts forecast that OR Royalties will post 0.62 EPS for the current year.

OR Royalties Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Wednesday, December 31st will be paid a dividend of $0.055 per share. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $0.22 annualized dividend and a yield of 0.6%. OR Royalties’s dividend payout ratio is presently 27.85%.

OR Royalties Company Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.